ALT Q3 2025 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena

ALTAltimmune, Inc.

$353M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5,000+0.0% YoY

Gross Profit

-$15M-299100.0% margin

Operating Income

-$21M-417180.0% margin

Net Income

-$19M-380280.0% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$218M

Total Liabilities

$33M

Stockholders' Equity

$186M

Cash & Equivalents

$61M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5,000	$5,000	+0.0%
Gross Profit	-$15M	$5,000	-299200.0%
Operating Income	-$21M	-$25M	+15.8%
Net Income	-$19M	-$23M	+16.8%